Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis.
We investigated whether glatiramer acetate (GA) treatment may affect Th1 differentiation at various T-cell maturation stages. Specifically, we analyzed the effect of in vivo GA treatment on intracellular synthesis of IL-2 and TNF-alpha by naive, memory and effector CD4(+) and CD8(+) T cells by five-colour flow cytometry. Our data indicate that GA treatment downregulates/normalizes an accelerated Th1 differentiation of CD4(+) T cells in RRMS patients at all stages of T-cell maturation. Most notably, we conclude that, by altering naive, unprimed CD4(+) T cells, GA treatment appears to affect T-cell differentiation, at least in part, in an antigen-independent manner.
Kantengwa
S
S
Department of Neurology, Neuroimmunology Laboratories, University Hospital of Geneva, Micheli-du-Crest 24, 1211 Geneva 14, Switzerland.
Weber
M S
MS
Juillard
C
C
Benkhoucha
M
M
Fellay
B
B
Zamvil
S S
SS
Gougeon
M-L
ML
Chofflon
M
M
Lalive
P H
PH
D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000096:biosynthesis; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use*; D018417:Th1 Cells; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000187:drug effects
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D000068717:Glatiramer Acetate